CDEK
← All drugs Report issue

peginterferon lambda-1a

Recombinant proteinexperimental

Clinical trial activity

30 trials · 23 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
26
Phase 3
10
Phase 4
0

Earliest trial started Dec 1, 2007 (NCT00565539)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hdv-interferon
  • peg-il-29
  • peg interferon lambda
  • peginterferon lambda
  • peginterferon lambda-1a
  • peginterferon lambda-1a
  • peg-ril-29
  • peg-ril-29
  • pegylated interferon lambda
  • pegylated-interferon-lambda
  • pegylated interferon lambda-1a
  • pegylated recombinant interleukin 29

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05953545Phase 2Jan 3, 2024National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05779995Phase 1/Phase 2 (Phase 2)Apr 20, 2023Sciwind Biosciences APAC CO Pty. Ltd., Sichuan University
NCT05070364Phase 3Dec 15, 2021Eiger BioPharmaceuticals
NCT05083117Phase 2Oct 30, 2021Hospital Nacional Arzobispo Loayza, Hospital Pirovano, Sciwind Biosciences APAC CO Pty. Ltd.
NCT04967430Phase 3Aug 27, 2021University of Toronto
NCT04727424Phase 3Jan 19, 2021Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA, Cytel Inc., Eiger BioPharmaceuticals, Fast Grants, McMaster University, RainWater Foundation
NCT05642403Phase 1Jan 3, 2021Sciwind Biosciences APAC CO Pty. Ltd., The Third Hospital of Changsha
NCT04534673Phase 2Aug 5, 2020Ben Gurion University
NCT04388709Phase 2May 31, 2020Eiger BioPharmaceuticals, Icahn School of Medicine at Mount Sinai
NCT04354259Phase 2May 13, 2020University of Toronto
NCT04343976Phase 2May 1, 2020Eiger BioPharmaceuticals, Harvard University
NCT04344600Phase 2Apr 30, 2020Eiger BioPharmaceuticals, Johns Hopkins University
NCT04331899Phase 2Apr 15, 2020Stanford University
NCT03600714Phase 2Aug 1, 2018National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02765802Phase 2Oct 19, 2016Eiger BioPharmaceuticals
NCT02063607Phase 1Dec 1, 2013Epoch Biosciences
NCT01866930Phase 3Jul 11, 2013Bristol-Myers Squibb
NCT01795911Phase 2Mar 1, 2013Bristol-Myers Squibb
NCT01754974Phase 3Mar 1, 2013Bristol-Myers Squibb
NCT01741545Phase 3Mar 1, 2013Bristol-Myers Squibb
Showing 20 of 30 trials
Page 1 / 2

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit121132010
Eiger BioPharmaceuticalsFor profit6222016
Sciwind Biosciences APAC CO Pty. Ltd.For profit3322021
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2212018
University of TorontoAcademic/Hospital2222020
ZymoGeneticsFor profit2222007
Avanti Polar Lipids, Inc.For profit1112008
Ben Gurion UniversityAcademic/Hospital1112020
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDAAcademic/Hospital1112021
Cytel Inc.For profit1012021
Epoch BiosciencesFor profit1112013
Fast GrantsAcademic/Hospital1012021
Global Hospital, HyderabadAcademic/Hospital1012008
Harvard UniversityAcademic/Hospital1112020
Hospital Nacional Arzobispo LoayzaAcademic/Hospital1012021
Hospital PirovanoAcademic/Hospital1012021
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112020
Johns Hopkins UniversityAcademic/Hospital1112020
McMaster UniversityAcademic/Hospital1012021
RainWater FoundationAcademic/Hospital1012021
23 organizations
Page 1 / 2